Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Belite Bio, Inc

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio to Host Webcast on March 17, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio to Participate in the Leerink Partners Global Healthcare Conference
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio Announces Interim Analysis Results from the Pivotal Global Phase 3 DRAGON trial of Tinlarebant in Adolescent Stargardt Disease Subjects
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio Announces Registered Direct Offering of $15 Million
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio to Participate in the Maxim Group 2024 Healthcare Virtual Summit
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio to Participate in Three Upcoming Investor Conferences
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio to Present at the JonesHealthcare Seaside Summit
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio Announces $25 Million Registered Direct Offering
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.